✦ LIBER ✦

CGS 22745: A selective orally active inhibitor of 5-lipoxygenase

✍ Scribed by E. Kimble; T. Kowalski; D. White; A. Raychauduri; G. Pastor; H. Chertock; W. Lee; R. Neale; A. Hamdan; J. Wasley

Publisher: SP Birkhäuser Verlag Basel
Year: 1991
Tongue: English
Weight: 244 KB
Volume: 34
Category: Article
ISSN: 1420-908X
DOI: 10.1007/bf01993256

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CGS 26529: The biological profile of a n

CGS 26529: The biological profile of a novel, orally active 5-lipoxygenase inhibitor with an extended duration of action

✍ E. Kimble; T. Kowalski; P. Peters; W. Lee; J. Koehler; A. Raychaudhuri; H. Chert 📂 Article 📅 1995 🏛 SP Birkhäuser Verlag Basel 🌐 English ⚖ 187 KB

The discovery and development of zileuto

The discovery and development of zileuton: An orally active 5-lipoxygenase inhibitor

✍ R.L. Bell; P.R. Young; D. Albert; C. Lanni; J.B. Summers; D.W. Brooks; P. Rubin; 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 425 KB

Methoxyalkyl thiazoles: A novel series o

Methoxyalkyl thiazoles: A novel series of potent, orally active and enantioselective inhibitors of 5-lipoxygenase

✍ R. M. McMillan; T. G. C. Bird; G. C. Crawley; M. P. Edwards; J. -M. Girodeau; J. 📂 Article 📅 1991 🏛 SP Birkhäuser Verlag Basel 🌐 English ⚖ 230 KB

Identification of a Novel 3,5-Disubstitu

Identification of a Novel 3,5-Disubstituted Pyridine as a Potent, Selective, and Orally Active Inhibitor of Akt1 Kinase.

✍ Sheela A. Thomas; et al. et al. 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 9 KB 👁 1 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.

Discovery of L-791,943: A Potent, Select

Discovery of L-791,943: A Potent, Selective, Non-Emetic and Orally Active Phosphodiesterase-4 Inhibitor.

✍ Daniel Guay; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 28 KB

Population pharmacokinetics of zileution

Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis

✍ W. M. Awni; G. R. Granneman; C. S. Locke; S. R. Brandwein; L. M. Dube 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 653 KB

The pharmacokinetics of zileuton, a novel selective 5-1ipoxygenase inhibitor, were studied in 37 patients with rheumatoid arthritis after administration of 200 mg, 400 rag, and 600 mg zileuton for 4 weeks. Patients had 6-h pharmacokinetic evaluation of zileuton on day 14. Plasma zileuton concentrati